Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study

James Chih Hsin Yang, Wu Chou Su, Chao Hua Chiu, Her Shyong Shiah, Kang Yun Lee, Te Chun Hsia, Makiko Uno, Nigel Crawford, Hiroshi Terakawa, Wen Chi Chen, Gensuke Takayama, Ching Hsu, Ying Hong, Carline Saintilien, Joseph McGill, Gee Chen Chang

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science